One quarter isn't enough data to be sure, of course. ABBV's 1Q19 HCV sales of $815M were inline with ABBV's 2019 guidance of $3.3B, but GILD's 1Q19 HCV sales of $790M were $90M above the midpoint of GILD's 2019 guidance range of $2.7-2.9B (which was reiterated yesterday), suggesting that subsequent quarters could be somewhat lighter.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.